Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059975 · ClinicalTrials.gov registry record · Early Phase 1
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
A Early Phase 1 study of Acute Myeloid Leukemia and Pediatric AML, sponsored by Joanna Yi.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07059975 is a Early Phase 1 study of Acute Myeloid Leukemia and Pediatric AML that is actively recruiting participants, run by Joanna Yi. The registered enrollment target is 36 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07059975, a Early Phase 1 study of Acute Myeloid Leukemia and Pediatric AML, is actively recruiting participants, sponsored by Joanna Yi.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve similar or better survival with chemotherapy cycles that are intensive but less likely to cause long-term complications. Patients will enroll on this trial at the end of their first induction cycle. The two cycles to be substituted are: * "Ida-FLA" (idarubicin+fludarabine/cytarabine) as Induction 2 * "VIA" (venetoclax+idarubicin+cytarabine) as Intensification 1 of the HR treatment regimen, and Intensification 2 of the IR treatment backbone. Researchers will evaluate side effects and outcomes for up to three years after enrollment. Participants will also have the opportunity to participate in optional research studies including patient surveys and blood and bone marrow sample testing.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Fludarabine
- DRUG Etoposide
- DRUG Idarubicin Hydrochloride
- DRUG Cytarabine (Ara-C)
Study Locations (1)
Texas
- Texas Children's Cancer and Hematology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2031-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07059975
The ClinicalTrials.gov registry entry for NCT07059975 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (69% lower). The listed sponsor is Joanna Yi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.
NCT07059975 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07059975 about?
NCT07059975 is a clinical study titled "UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML". This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve s...
What is the current status of trial NCT07059975?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2025-10-22. Estimated completion is 2031-08.
What conditions does trial NCT07059975 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Pediatric AML.
What interventions are being tested in trial NCT07059975?
The interventions under investigation include: Venetoclax (DRUG), Fludarabine (DRUG), Etoposide (DRUG), Idarubicin Hydrochloride (DRUG), Cytarabine (Ara-C) (DRUG).
Who is sponsoring clinical trial NCT07059975?
This trial is sponsored by Joanna Yi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07059975 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RECRUITING · Early Phase 1
-
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
RECRUITING · Early Phase 1
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
COMPLETED · Early Phase 1
-
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
COMPLETED · Early Phase 1
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.